Drug
GS 3242
GS 3242: highest development phase Phase 2/3, developed by Gilead Sciences. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| GS-3242 Tablet NCT07708727 | Phase 2/3 | HIV-1-infection |
| GS-3242 Tablet NCT07645287 | Phase 2 | HIV-1-infection |
| GS-3242 NCT07001319 | Phase 1 | HIV-1-infection |
Latest
No recent events.
Follow GS 3242 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.